Correlates of protection for booster doses of the BNT162b2 vaccine
Authors:
Preprint
Abstract
Introduction Variants of concern (VOC) of SARS-CoV2 and waning immunity pose a serious global problem. Herein, we aimed to identify novel correlates of protection (COPs) against symptomatic SARS-CoV-2 infection. Methods We conducted a Multicenter prospective study assessing the association between serological profiles and the risk for SARS-CoV-2 infection, comparing those vaccinated with three to four doses of Pfizer BNT162b2 vaccine. Results Of 608 healthy adults, 365 received three doses and 243 received four doses. During the first 90 days of followup, 239 (39%) were infected, of whom 165/365 (45%) received 3 doses and 74/243 (30%) four doses. We found that the fourth dose elicited a significant rise in antibody binding and neutralizing titers against multiple variants, and reduced the risk of symptomatic infection by 37% [95% I, 15% - 54%]. We found several binding IgG and IgA markers and their combinations that were COPs. The strongest association with infection risk was IgG levels to RBD mutants and IgA levels to VOCs, which was a COP in the three-dose group (HR=6.34, p=0.008) and in the four-dose group (HR=8.14, p=0.018). A combination of two commercially available ELISA assays were also associated with protection in both groups (HR = 1.84, p = 0.002; HR = 2.01, p = 0.025, respectively). In a subset, comparing those with low to high antibody levels before 4th dose, despite a significant rise in neutralizing antibody titers against both omicron variants, the number of infections in the low group (n=16) was significantly higher than in the high group (n=7, 43% vs. 20%, p=0.051). Conclusions We demonstrated that following immunization with three or four vaccine doses, combinations of IgA and IgG levels are associated with protection from symptomatic infection. In addition, we identified a subpopulation of healthy adult individuals with low-baseline levels of antibodies after 3 doses which are at an increased risk for SARS-CoV-2 infection despite receiving a fourth dose. These findings warrant further study of this group, assessing whether they are at a higher risk for developing severe disease or may spread infection more readily than others.Keywords
This publication has 33 references indexed in Scilit:
- Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance dataThe Lancet, 2021
- Longitudinal Development of Antibody Responses in COVID-19 Patients of Different Severity with ELISA, Peptide, and Glycan Arrays: An Immunological Case SeriesPathogens, 2021
- Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraCell, 2021
- Array-based analysis of SARS-CoV-2, other coronaviruses, and influenza antibodies in convalescent COVID-19 patientsBiosensors and Bioelectronics, 2020
- Linear epitopes of SARS-CoV-2 spike protein elicit neutralizing antibodies in COVID-19 patientsCellular & Molecular Immunology, 2020
- SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responsesNature Communications, 2020
- Novel correlates of protection against pandemic H1N1 influenza A virus infectionNature Medicine, 2019
- Spec-seq unveils transcriptional subpopulations of antibody-secreting cells following influenza vaccinationJournal of Clinical Investigation, 2018
- Strong Clonal Relatedness between Serum and Gut IgA despite Different Plasma Cell OriginsCell Reports, 2017
- An Intranasal Proteosome-Adjuvanted Trivalent Influenza Vaccine Is Safe, Immunogenic & Efficacious in the Human Viral Influenza Challenge Model. Serum IgG & Mucosal IgA Are Important Correlates of Protection against Illness Associated with InfectionPLOS ONE, 2016